Let those numbers sink in
Conclusions These findings suggest a potentially elevated risk of vision impairment with semaglutide use compared to other diabetes and weight loss medications, warranting further investigation and vigilant post-marketing surveillance
A dedicated phase 2a substudy in people with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) used MRI to measure liver fat and found that, after 24 weeks, retatrutide reduced relative liver-fat content by about 81% at the 8 mg dose and about 82% at 12 mg, versus essentially no change on placebo
If you have tried other diets without success and can commit to a 30 or 60-day plan with a doctors supervision, call Regenerate Medical Concierge today to schedule a consultation
The Toronto-based company had paused research and development while pursuing financing
When we carry more weight, the skin stretches and accommodates